Viiv’s Cabotegravir Shows Superiority Over Truvada as PrEP Among Women

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

ViiV unblinded the Phase III study on positive data, and it plans to pursue approval in H1 2021.

Pills for Pre-Exposure Prophylaxis (PrEP) to prevent HIV with PrEP text engraved

Data from the Phase III study of ViiV Healthcare’s injected drug for pre-exposure prophylaxis (PrEP) against HIV infection among cisgender women will likely bolster its chances of winning regulatory approval across gender groups, following the release earlier this year of positive data in men who have sex with men (MSM) and transgender women. The bigger question now is how it will fit into the overall treatment paradigm, given competition from the two approved oral drugs.

ViiV said 9 November that the data safety monitoring board (DSMB) for the Phase III HPTN 084 study of cabotegravir...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D